1. In Vivo

Globus Prepared for Trek with $110m from Clarus-led Group

Clarus Ventures placed an unusually big bet for the orthopedics industry by leading a syndicate of private equity investors in a $110 million Series E round in Globus Medical Inc. But the four-year-old company is well ahead of its peers with more than $100 million in sales and a line of fusion products on the market. The company faces the challenge of introducing a new line of non-fusion and biomaterial products if it hopes to grow into the industry leader its investors expects it to be.

Investors in orthopedics traditionally have backed companies with technologies compelling enough to draw the interest of giants on the industry’s mountaintop—Medtronic Inc. ’s Medtronic Sofamor Danek , Johnson & Johnson ’s Depuy Spine Inc. , Synthes-Stratec ’s Synthes USA , Stryker Corp., and Zimmer Spine (a division of Zimmer Holdings Inc.’s Centerpulse AG)--controllers of 70% of the $4.3 billion US spine market. (See "The Hot Trend in Spine: Motion Preservation Mania," Medtech Insight, June 2007 Also see "The Hot Trend in Spine: Motion Preservation Mania" - Medtech Insight, 1 June, 2007..)

Last month, Clarus Ventures and a syndicate of private equity investors opted instead to invest heavily—unusually heavily for the orthopedics...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Deals Shaping The Industry, June 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.